188 related articles for article (PubMed ID: 29574193)
61. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
62. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys.
Kakinoki M; Sawada O; Sawada T; Saishin Y; Kawamura H; Ohji M
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5877-80. PubMed ID: 22836776
[TBL] [Abstract][Full Text] [Related]
63. Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.
Barzelay A; Lowenstein A; George J; Barak A
Curr Eye Res; 2010 Sep; 35(9):835-41. PubMed ID: 20795866
[TBL] [Abstract][Full Text] [Related]
64. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
[TBL] [Abstract][Full Text] [Related]
65. Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Dana P; Fujikawa S; Matsuda K; Ohkuma K; Kudo E; Kraiklang R; Wongkham C; Wongkham S; Okada S
Tumour Biol; 2016 Jul; 37(7):9023-35. PubMed ID: 26762407
[TBL] [Abstract][Full Text] [Related]
66. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
67. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
68. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
[TBL] [Abstract][Full Text] [Related]
69. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
70. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells.
Spitzer MS; Wallenfels-Thilo B; Sierra A; Yoeruek E; Peters S; Henke-Fahle S; Bartz-Schmidt KU; Szurman P;
Br J Ophthalmol; 2006 Oct; 90(10):1316-21. PubMed ID: 16723358
[TBL] [Abstract][Full Text] [Related]
71. Tricin, 4',5,7-trihydroxy-3',5'-dimethoxyflavone, exhibits potent antiangiogenic activity in vitro.
Han JM; Kwon HJ; Jung HJ
Int J Oncol; 2016 Oct; 49(4):1497-504. PubMed ID: 27498749
[TBL] [Abstract][Full Text] [Related]
72. VEGF111b, a new member of VEGFxxxb isoforms and induced by mitomycin C, inhibits angiogenesis.
Gu F; Li X; Kong J; Pan B; Sun M; Zheng L; Yao Y
Biochem Biophys Res Commun; 2013 Nov; 441(1):18-24. PubMed ID: 24125722
[TBL] [Abstract][Full Text] [Related]
73. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
Minion LE; Tewari KS
Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
[TBL] [Abstract][Full Text] [Related]
74. Validation of Cross-Species Reactivity of the VEGF-A/PDGFRβ Bifunctional Antibody PF-06653157.
Ashoor R; Lee D; Cheng A; Jessen B; Huang W
J Ocul Pharmacol Ther; 2016 Dec; 32(10):650-658. PubMed ID: 27736501
[TBL] [Abstract][Full Text] [Related]
75. NTP technical report on the toxicology and carcinogenesis studies of 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (Gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 May; (529):4-168. PubMed ID: 16835634
[TBL] [Abstract][Full Text] [Related]
76. An apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism.
Wang K; Stark FS; Schlothauer T; Lahr A; Cosson V; Zhi J; Habben K; Tessier J; Schick E; Staack RF; Krieter O
Cancer Chemother Pharmacol; 2017 Apr; 79(4):661-671. PubMed ID: 28314990
[TBL] [Abstract][Full Text] [Related]
77. Species Cross-Reactivity of Antibodies Used to Treat Ophthalmic Conditions.
Irani Y; Scotney P; Nash A; Williams KA
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):586-91. PubMed ID: 26886891
[TBL] [Abstract][Full Text] [Related]
78. Effect of anti-VEGF antibody on retinal ganglion cells in rats.
Iriyama A; Chen YN; Tamaki Y; Yanagi Y
Br J Ophthalmol; 2007 Sep; 91(9):1230-3. PubMed ID: 17475701
[TBL] [Abstract][Full Text] [Related]
79. VEGF-A inhibition ameliorates podocyte apoptosis via repression of activating protein 1 in diabetes.
Bai X; Geng J; Li X; Yang F; Tian J
Am J Nephrol; 2014; 40(6):523-34. PubMed ID: 25572464
[TBL] [Abstract][Full Text] [Related]
80. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
